Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (S <u>EASI</u> DE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing

Rademikibart Q2W induced rapid improvements in AD lesions and pruritus during the initial 16 weeks, which were maintained/improved further with rademikibart Q2W or Q4W across an additional 36 weeks. Rademikibart Q2W and Q4W were similarly efficacious and well tolerated. These findings are compatible with those from the published international phase II rademikibart trial, CBP-201-WW001.